Literature DB >> 33831253

Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Zachary J Brown1, Jordan M Cloyd1.   

Abstract

For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  FOLFIRINOX; neoadjuvant chemotherapy; pancreatic cancer; pancreatoduodenectomy; preoperative therapy; whipple

Mesh：

Substances：

Year:  2021        PMID： 33831253     DOI： 10.1002/jso.26384

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  5 in total

1.  Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.

Authors:  Lena Stevens; Zachary J Brown; Ryan Zeh; Christina Monsour; Sharla Wells-Di Gregorio; Heena Santry; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

2.  Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.

Authors:  Zachary J Brown; Hanna E Labiner; Chengli Shen; Aslam Ejaz; Timothy M Pawlik; Jordan M Cloyd
Journal:  J Surg Oncol       Date:  2021-10-02       Impact factor: 2.885

3.  Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd
Journal:  HPB (Oxford)       Date:  2021-10-25       Impact factor: 3.842

Review 4.  Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Martijn A van Dam; Floris A Vuijk; Judith A Stibbe; Ruben D Houvast; Saskia A C Luelmo; Stijn Crobach; Shirin Shahbazi Feshtali; Lioe-Fee de Geus-Oei; Bert A Bonsing; Cornelis F M Sier; Peter J K Kuppen; Rutger-Jan Swijnenburg; Albert D Windhorst; Jacobus Burggraaf; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

Review 5.  Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?

Authors:  Eva Versteijne; Ignace H J T de Hingh; Marjolein Y V Homs; Martijn P W Intven; Joost M Klaase; Hjalmar C van Santvoort; Judith de Vos-Geelen; Johanna W Wilmink; Geertjan van Tienhoven
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.